Backgrounds/Aims: Postoperative diabetes mellitus (DM) after pancreaticoduodenectomy (PD) may compromise the long-term quality of life in survivors after the operative procedure due to the treatment difficulty and its related complications. The aim of this study is to determine the incidence of new-onset pancreatogenic DM after PD and investigate the risk factors for this complication. Methods: Among 170 patients who had undergone PD between November 2003 and September 2009, 98 patients were selected for this study. The selected patients were non-diabetic prior to the operation and had undergone follow-up tests for glucose metabolism and an abdominal computed tomography (CT) scan 1 year after the operation. The clinical data of these patients were retrospectively analyzed by reviewing the medical records, radiologic images, and pathologic reports. Results: Postoperative pathology confirmed malignant tumors in 91 patients, borderline malignancy in 5, and benign tumor in 2. The tumor locations included the pancreatic head (n=30), the common bile duct (CBD) (n=30), ampulla of Vater (n=30), and the duodenum (n=8). New-onset DM occurred in 17 (17.4%) of the 98 patients during the first year after the operation. The comparative analysis between postoperative DM (＋) and DM (−) groups revealed that the atrophy of the remaining pancreas was the only significant risk factor for development of postoperative DM after PD. Conclusions: This study suggests that the atrophy of the remaining pancreas increases the risk of pancreatogenic DM after PD, and efforts to prevent pancreatic atrophy are needed to decrease this complication. 
INTRODUCTION
There is limited data on the long-term quality of life of the patients following the pancreaticoduodenectomy (PD), mainly due to the poor prognosis of the malignant disease constituting the major indications for this operative procedure, along with the high postoperative morbidity and mortality rates. However, the long-term survival rate has recently increased due to the refined surgical techniques, improvement in perioperative management, development of adjuvant treatments, and more frequent use of PD in benign and borderline malignant tumors. 1 The improved survival after PD has led to an increased concern regarding the long-term metabolic consequences. 2, 3 The loss of pancreatic parenchyma resulting from pancreatectomy can lead to the abnormality in the glucose homeostasis known as pancreatogenic diabetes mellitus (DM). Impairment of the glucose metabolism after PD is difficult to predict and can range from minimal to major metabolic derangements. Although pancreatic insufficiency is generally known to occur when more than 80% of the pancreas is resected, new-onset DM has been reported to develop in 20-50% of the patients even after PD involving the removal of approximately 40-50% of pancreatic volume. 1, 4 Pancreatogenic DM can compromise the long-term quality of life of the patients, because it is frequently associated with iatrogenic hypoglycemia resulting from increased peripheral sensitivity to insulin, unlike other types of DM; hence, it is difficult to control with medication. Long-term inadequate glycemic control can also cause nephropathy, neuropathy, and retinopathy.
Therefore, it is important to evaluate the incidence of pancreatogenic DM after PD, and identify the risk factors of developing this complication. Previous studies on pancreatogenic DM mainly examined the changes in hormone secretion or glucose metabolism after pancreatectomy. 2, 5 There have been few clinical studies which have aimed to identify the risk factors associated with pancreatogenic DM. 6 In this study, we investigated the frequency of occurrence of new-onset pancreatogenic DM after PD, and analyzed the risk factors associated with the complication.
METHODS

Patients
The 
Definition of parameters
All patients underwent glucose metabolism tests, including oral glucose tolerance test (OGTT), as well as an abdominal computed tomography (CT), before and one year after the operation. In the OGTT, the blood glucose was measured after fasting and two hours after drinking a glucose-rich beverage. Pancreatogenic DM was defined as the presence of diabetes symptoms, a random glucose level ＞200 mg/dl, fasting blood sugar (FBS) ＞126 mg/dl, or postprandial glucose level ＞140 mg/dl. The pancreatic-duct was defined to be dilated when it was five mm or more in diameter on the postoperative CT images. The thickness of the pancreatic parenchyma near the pancreatoenteric anastomosis site was measured using an abdominal CT, before and one year after the operation.
Pancreatic atrophy was confirmed when the postoperative parenchymal thickness was reduced to ＜50% of the preoperative value. The presence of pancreatitis was evaluated by postoperative pathologic examination.
Statistics
In order to determine the risk factors for development of diabetes, the categorical variables were compared using chi-square test, and the continuous variables were compared using the non-parametric Mann-Whitney U test. All the statistical analysis was performed using the SPSS version 19.0 for Windows (SPSS Inc., Chicago, IL, USA).
A p-value less than 0.05 was considered statistically significant.
RESULTS
Demographic characteristics
The demographic characteristics of the study population were summarized in 
Risk factors for postoperative DM
In the follow-up of one year after the operation, postoperative new-onset DM (NODM) had developed in 17 (17.4%) of the 98 patients. To control the possible bias, this study was designed with patients who were non-diabetic preoperatively, with the evaluation of their glucose metabolism function at the same time-interval after operation. The results show that NODM occurred in 17% of the non-diabetic patients who underwent PD during the follow-up of one year after the operation. This is consistent with the results of the previous studies that reported the incidence rate of 9-20% of pancreatogenic diabetes after PD. 3, 19 This finding indicates that the impairment of pancreatic endocrine function may develop after some degree of resection, unlike the exocrine function that may not be hampered even after the Moreover, this incidence is expected to increase throughout the remaining life of the patients, because glucose tolerance function naturally decreases with age, and the process of pancreatic atrophy may continue over time. 9 Therefore, the endocrine function of patients with a long life expectancy after PD should be carefully monitored in order to early detect diabetes and to avoid the long-term complications caused by inadequate glycemic control.
Another important finding of this study is that among various clinicopathologic factors, postoperative pancreatic atrophy was the only risk factor for pancreatogenic DM after PD. The pancreatic atrophy after pancreatic head resection resulted in the loss of endocrine function of pancreas. 3, 9 This finding is contradictory to the previous study of You et al. 3 which showed that the volume of the Atrophy of the remnant distal pancreas after PD commonly occurs, and there have been several animal and human studies in the attempts of preventing the pancreas atrophy. 9 Although the mechanism is not well elucidated, a suggested mechanism involves the loss of gastrointestinal hormones with the trophic effect on the pancreas, such as cholecystokinin and gastrin, resulting from the resection of the duodenum and the distal stomach.
Jang et al. reported that induced hypergastrinemia can prevent pancreatic atrophy after PPPD, likely via a mechanism of the regenerative activity of the pancreas stimulated by gastrin. 9 Additionally, a recent animal study showed that control of serum glucose levels play an important role in preventing pancreatic atrophy. 10 Based on the result of these studies, the efforts to prevent pancreatic atrophy should be continued and clinically applied to de-crease the incidence of pancreatogenic DM after PD.
In conclusion, this study suggests that pancreatogenic DM is not an uncommon complication after PD, and that postoperative atrophy of the remaining pancreas significantly increases the risks of this complication. As such, patients who undergo PD need to be carefully followed up, in order to monitor the glucose metabolism function in avoiding the DM related long-term complications and improving their quality of life. In addition, various efforts to prevent the atrophy of the remaining pancreas are required to decrease this complication.
